Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Jan 20, 2026, 16:34Fernanda Orsi Explores Brazilian Registry of Thrombotic Thrombocytopenic Purpura
-
Jan 20, 2026, 16:15Tareq Abadl on Bacterial Contamination of Platelets
-
Jan 20, 2026, 15:53Ruzanna Papyan on Neuroblastoma Risk Stratification in Real-World Settings
-
Jan 20, 2026, 13:35Omar Shaltout On Stories Behind Memorable Cases
-
Jan 20, 2026, 13:25Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
-
Jan 20, 2026, 13:15Benjamin YQ Tan on Precision Lipid Management After Stroke
-
Jan 20, 2026, 13:08Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
-
Jan 20, 2026, 12:33Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
-
Jan 20, 2026, 12:18Ed Shovelin on CRP-A Utilization in Diverse Research Areas